{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T13:44:57Z","timestamp":1794059097010,"version":"4.8.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T00:00:00Z","timestamp":1767484800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100018090","name":"Bayer Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018090","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-31287-5","type":"journal-article","created":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T14:33:27Z","timestamp":1767537207000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Short-term outcomes and choroidal morphological changes following aflibercept therapy in pachychoroid neovasculopathy"],"prefix":"10.1038","volume":"16","author":[{"given":"Jae Hui","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Min","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soon Il","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Ik","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joonhong","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Ki","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,4]]},"reference":[{"key":"31287_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/IAE.0000000000000331","volume":"35","author":"CE Pang","year":"2015","unstructured":"Pang, C. E. & Freund, K. B. Pachychoroid neovasculopathy. Retina 35, 1\u20139 (2015).","journal-title":"Retina"},{"key":"31287_CR2","doi-asserted-by":"publisher","DOI":"10.1177\/11206721211036290","author":"P Sagar","year":"2021","unstructured":"Sagar, P., Sodhi, P. S., Roy, S., Takkar, B. & Azad, S. V. Pachychoroid neovasculopathy: A comparative review on pathology, clinical features, and therapy. Eur J. Ophthalmol https:\/\/doi.org\/10.1177\/11206721211036290 (2021).","journal-title":"Eur J. Ophthalmol"},{"key":"31287_CR3","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/s41433-024-03253-4","volume":"39","author":"CMG Cheung","year":"2025","unstructured":"Cheung, C. M. G. et al. Pachychoroid disease: review and update. Eye (Lond). 39, 819\u2013834 (2025).","journal-title":"Eye (Lond)"},{"key":"31287_CR4","doi-asserted-by":"publisher","first-page":"4999","DOI":"10.1038\/s41598-021-84650-7","volume":"11","author":"YH Kim","year":"2021","unstructured":"Kim, Y. H., Lee, B., Kang, E. & Oh, J. Clustering of eyes with age-related macular degeneration or pachychoroid spectrum diseases based on choroidal thickness profile. Sci. Rep. 11, 4999 (2021).","journal-title":"Sci. Rep."},{"key":"31287_CR5","doi-asserted-by":"publisher","first-page":"16204","DOI":"10.1038\/srep16204","volume":"5","author":"M Miyake","year":"2015","unstructured":"Miyake, M. et al. Pachychoroid neovasculopathy and age-related macular degeneration. Sci. Rep. 5, 16204 (2015).","journal-title":"Sci. Rep."},{"key":"31287_CR6","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s00417-020-04957-5","volume":"259","author":"M Pellegrini","year":"2021","unstructured":"Pellegrini, M. et al. Short-term choroidal vascular changes after Aflibercept therapy for neovascular age-related macular degeneration. Graefes Arch. Clin. Exp. Ophthalmol. 259, 911\u2013918 (2021).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"31287_CR7","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1136\/bjophthalmol-2015-308074","volume":"100","author":"JH Kim","year":"2016","unstructured":"Kim, J. H., Lee, T. G., Chang, Y. S., Kim, C. G. & Cho, S. W. Short-term choroidal thickness changes in patients treated with either Ranibizumab or aflibercept: a comparative study. Br. J. Ophthalmol. 100, 1634\u20131639 (2016).","journal-title":"Br. J. Ophthalmol."},{"key":"31287_CR8","doi-asserted-by":"publisher","first-page":"3580","DOI":"10.3390\/jcm10163580","volume":"10","author":"JH Kim","year":"2021","unstructured":"Kim, J. H., Kim, J. W. & Kim, C. G. Investigation of the Trend of Selecting Anti-Vascular Endothelial Growth Factor Agents for the Initial Treatment of Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy. J Clin. Med 10, 3580 (2021).","journal-title":"J Clin. Med"},{"key":"31287_CR9","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1167\/iovs.17-22144","volume":"59","author":"N Padr\u00f3n-P\u00e9rez","year":"2018","unstructured":"Padr\u00f3n-P\u00e9rez, N. et al. Changes in choroidal thickness after intravitreal injection of Anti-Vascular endothelial growth factor in pachychoroid neovasculopathy. Invest. Ophthalmol. Vis. Sci. 59, 1119\u20131124 (2018).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"31287_CR10","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s12886-021-02022-1","volume":"21","author":"B Schworm","year":"2021","unstructured":"Schworm, B. et al. Vanishing pachy-choroid in pachychoroid neovasculopathy under long-term anti-vascular endothelial growth factor therapy. BMC Ophthalmol. 21, 269 (2021).","journal-title":"BMC Ophthalmol."},{"key":"31287_CR11","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1038\/s41598-019-38504-y","volume":"9","author":"BJ Jung","year":"2019","unstructured":"Jung, B. J. et al. Intravitreal Aflibercept and Ranibizumab for pachychoroid neovasculopathy. Sci. Rep. 9, 2055 (2019).","journal-title":"Sci. Rep."},{"key":"31287_CR12","doi-asserted-by":"publisher","first-page":"4411","DOI":"10.1038\/s41598-018-22745-4","volume":"8","author":"J Zhao","year":"2018","unstructured":"Zhao, J. et al. Macular choroidal Small-Vessel layer, sattler\u2019s layer and haller\u2019s layer thicknesses: the Beijing eye study. Sci. Rep. 8, 4411 (2018).","journal-title":"Sci. Rep."},{"key":"31287_CR13","doi-asserted-by":"publisher","first-page":"8439","DOI":"10.1038\/s41598-020-65370-w","volume":"10","author":"B Schworm","year":"2020","unstructured":"Schworm, B. et al. Ranibizumab non-response in pachychoroid neovasculopathy: effects of switching to Aflibercept. Sci. Rep. 10, 8439 (2020).","journal-title":"Sci. Rep."},{"key":"31287_CR14","first-page":"e68174","volume":"16","author":"MY Choi","year":"2024","unstructured":"Choi, M. Y. & Lee, W. K. Treatment and characteristics of pachychoroid neovasculopathy accompanying recalcitrant intraretinal cysts. Cureus 16, e68174 (2024).","journal-title":"Cureus"},{"key":"31287_CR15","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1007\/s00417-024-06582-y","volume":"262","author":"Y Fukuda","year":"2024","unstructured":"Fukuda, Y. et al. Three-month outcomes of treatment with faricimab or Aflibercept for neovascular age-related macular degeneration: a propensity score matching study in a Japanese population. Graefes Arch. Clin. Exp. Ophthalmol. 262, 3971\u20133978 (2024).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"31287_CR16","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1007\/s00417-024-06387-z","volume":"262","author":"N Tanaka","year":"2024","unstructured":"Tanaka, N. et al. Intravitreal anti-vascular endothelial growth factor and combined photodynamic therapy for pachychoroid neovasculopathy: long-term treatment outcomes. Graefes Arch. Clin. Exp. Ophthalmol. 262, 1811\u20131818 (2024).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"31287_CR17","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1167\/iovs.16-20967","volume":"58","author":"M Hata","year":"2017","unstructured":"Hata, M. et al. Intraocular vascular endothelial growth factor levels in pachychoroid neovasculopathy and neovascular Age-Related macular degeneration. Invest. Ophthalmol. Vis. Sci. 58, 292\u2013298 (2017).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"31287_CR18","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2147\/OPTH.S448507","volume":"18","author":"A Tanaka","year":"2024","unstructured":"Tanaka, A. et al. Short-Term outcomes of 3 monthly intravitreal faricimab on different subtypes of neovascular Age-Related macular degeneration. Clin. Ophthalmol. 18, 507\u2013516 (2024).","journal-title":"Clin. Ophthalmol."},{"key":"31287_CR19","doi-asserted-by":"publisher","first-page":"7379","DOI":"10.1038\/s41598-023-33936-z","volume":"13","author":"A Kuranami","year":"2023","unstructured":"Kuranami, A., Maruko, R., Maruko, I., Hasegawa, T. & Iida, T. Pachychoroid neovasculopathy has clinical properties that differ from conventional neovascular age-related macular degeneration. Sci. Rep. 13, 7379 (2023).","journal-title":"Sci. Rep."},{"key":"31287_CR20","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1089\/jop.2018.0107","volume":"35","author":"HJ Cho","year":"2019","unstructured":"Cho, H. J. et al. Intravitreal Anti-Vascular endothelial growth factor treatment for pachychoroid neovasculopathy. J. Ocul Pharmacol. Ther. 35, 174\u2013181 (2019).","journal-title":"J. Ocul Pharmacol. Ther."},{"key":"31287_CR21","doi-asserted-by":"publisher","first-page":"18272","DOI":"10.1038\/s41598-020-75506-7","volume":"10","author":"G Ryu","year":"2020","unstructured":"Ryu, G., Moon, C., van Hemert, J. & Sagong, M. Quantitative analysis of choroidal vasculature in polypoidal choroidal vasculopathy using ultra-widefield indocyanine green angiography. Sci. Rep. 10, 18272 (2020).","journal-title":"Sci. Rep."},{"key":"31287_CR22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1167\/iovs.62.15.5","volume":"62","author":"M Shen","year":"2021","unstructured":"Shen, M. et al. Choroidal changes in eyes with polypoidal choroidal vasculopathy after Anti-VEGF therapy imaged with Swept-Source OCT angiography. Invest. Ophthalmol. Vis. Sci. 62, 5 (2021).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"31287_CR23","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1159\/000521071","volume":"245","author":"D Montorio","year":"2022","unstructured":"Montorio, D., Giordano, M., Concilio, M. & Cennamo, G. Structural and vascular changes of the choroid in polypoidal choroidal vasculopathy after intravitreal Anti-VEGF therapy. Ophthalmologica 245, 173\u2013178 (2022).","journal-title":"Ophthalmologica"},{"key":"31287_CR24","doi-asserted-by":"publisher","first-page":"11389","DOI":"10.1038\/s41598-019-47738-9","volume":"9","author":"N Nagai","year":"2019","unstructured":"Nagai, N. et al. Dynamic changes in choroidal conditions during anti-vascular endothelial growth factor therapy in polypoidal choroidal vasculopathy. Sci. Rep. 9, 11389 (2019).","journal-title":"Sci. Rep."},{"key":"31287_CR25","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","volume":"403","author":"P Lanzetta","year":"2024","unstructured":"Lanzetta, P. et al. Intravitreal Aflibercept 8\u00a0mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet 403, 1141\u20131152 (2024).","journal-title":"Lancet"},{"key":"31287_CR26","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/jamaophthalmol.2023.2421","volume":"141","author":"CC Wykoff","year":"2023","unstructured":"Wykoff, C. C. et al. Effect of High-Dose intravitreal Aflibercept, 8\u00a0mg, in patients with neovascular Age-Related macular degeneration: the phase 2 CANDELA randomized clinical trial. JAMA Ophthalmol. 141, 834\u2013842 (2023).","journal-title":"JAMA Ophthalmol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31287-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31287-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31287-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T12:59:24Z","timestamp":1768395564000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31287-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,4]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["31287"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-31287-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,4]]},"assertion":[{"value":"24 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1798"}}